A PHASE 1/2, OPEN-LABEL TRIAL TO EVALUATE SAFETY, IMMUNOGENICITY, AND ANTI-TUMOR ACTIVITY OF VB10.16 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE RECURRENT OR METASTATIC HPV16-POSITIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA

Registry ID

VB-C-03

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

NYKODE THERAPEUTICS ASA

Last update

2026-06-26

Conditions

• SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Related clinical trials

• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PETOSEMTAMAB PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC PD-L1+ HEAD AND NECK SQUAMOUS CELL CARCINOMA.
• A PHASE 3 OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PETOSEMTAMAB COMPARED WITH INVESTIGATOR¿S CHOICE MONOTHERAPY TREATMENT IN PREVIOUSLY TREATED PATIENTS WITH INCURABLE, METASTATIC/RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE DOSTARLIMAB AS SEQUENTIAL THERAPY AFTER CHEMORADIATION IN PARTICIPANTS WITH LOCALLY ADVANCED UNRESECTED HEAD AND NECK SQUAMOUS CELL CARCINOMA
• A PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF VOLRUSTOMIG (MEDI5752) AS SEQUENTIAL THERAPY VERSUS OBSERVATION IN PARTICIPANTS WITH UNRESECTED LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY (EVOLVE-HNSCC)
• A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTOCOL TO EVALUATE NOVEL IMMUNOTHERAPY COMBINATIONS AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

View on source registry